The review was ordered by Department of Health and Human Services (HHS) Secretary Sebelius, to assess our nation’s readiness for future public health emergencies. The review also answered a charge by President Obama to improve our nation’s capacity to respond faster and more effectively to chemical, biological, radiological, nuclear (CBRN), and emerging infectious disease threats, such as pandemic influenza.
FDA’s Office of Counterterrorism and Emerging Threats (OCET) was asked to manage the implementation of MCMi. MCMi builds on programs already under way at FDA medical product centers, and devotes additional resources to foster the development and availability of medical products that will be needed to counter public health emergencies.
Read Commissioner Hamburg's remarks from the Medical Countermeasures Review roll-out